Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Low-Dose and Long-Term Olaparib Treatment Sensitizes MDA-MB-231 and SUM1315 Triple-Negative Breast Cancers Spheroids to Fractioned Radiotherapy.

Dubois C, Martin F, Hassel C, Magnier F, Daumar P, Aubel C, Guerder S, Mounetou E, Penault-Lorca F, Bamdad M.

J Clin Med. 2019 Dec 26;9(1). pii: E64. doi: 10.3390/jcm9010064.

2.

The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids from MDA-MB-231 and SUM1315 Triple-Negative Breast Cancer Cell Lines.

Dubois C, Daumar P, Aubel C, Gauthier J, Vidalinc B, Mounetou E, Penault-Llorca F, Bamdad M.

J Clin Med. 2019 Mar 21;8(3). pii: E397. doi: 10.3390/jcm8030397.

3.

Development and validation of a high-performance liquid chromatography method for the quantitation of intracellular PARP inhibitor Olaparib in cancer cells.

Daumar P, Dufour R, Dubois C, Penault-Llorca F, Bamdad M, Mounetou E.

J Pharm Biomed Anal. 2018 Apr 15;152:74-80. doi: 10.1016/j.jpba.2018.01.036. Epub 2018 Jan 31.

PMID:
29414021
4.

Development and cytotoxic response of two proliferative MDA-MB-231 and non-proliferative SUM1315 three-dimensional cell culture models of triple-negative basal-like breast cancer cell lines.

Dubois C, Dufour R, Daumar P, Aubel C, Szczepaniak C, Blavignac C, Mounetou E, Penault-Llorca F, Bamdad M.

Oncotarget. 2017 Aug 24;8(56):95316-95331. doi: 10.18632/oncotarget.20517. eCollection 2017 Nov 10.

5.

BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib.

Dufour R, Daumar P, Mounetou E, Aubel C, Kwiatkowski F, Abrial C, Vatoux C, Penault-Llorca F, Bamdad M.

Sci Rep. 2015 Aug 3;5:12670. doi: 10.1038/srep12670.

6.

Synthesis and evaluation of (18)F-labeled ATP competitive inhibitors of topoisomerase II as probes for imaging topoisomerase II expression.

Daumar P, Zeglis BM, Ramos N, Divilov V, Sevak KK, Pillarsetty N, Lewis JS.

Eur J Med Chem. 2014 Oct 30;86:769-81. doi: 10.1016/j.ejmech.2014.09.019. Epub 2014 Sep 8.

7.

Efficient (18)F-labeling of large 37-amino-acid pHLIP peptide analogues and their biological evaluation.

Daumar P, Wanger-Baumann CA, Pillarsetty N, Fabrizio L, Carlin SD, Andreev OA, Reshetnyak YK, Lewis JS.

Bioconjug Chem. 2012 Aug 15;23(8):1557-66. doi: 10.1021/bc3000222. Epub 2012 Jul 30.

8.

The next generation of positron emission tomography radiopharmaceuticals in oncology.

Rice SL, Roney CA, Daumar P, Lewis JS.

Semin Nucl Med. 2011 Jul;41(4):265-82. doi: 10.1053/j.semnuclmed.2011.02.002. Review.

9.

Design, synthesis and in vitro drug release investigation of new potential 5-FU prodrugs.

Daumar P, Decombat C, Chezal JM, Debiton E, Madesclaire M, Coudert P, Galmier MJ.

Eur J Med Chem. 2011 Jul;46(7):2867-79. doi: 10.1016/j.ejmech.2011.04.010. Epub 2011 Apr 14.

PMID:
21530016

Supplemental Content

Loading ...
Support Center